We aim to discuss the potential causes of ECS, evaluate the effectiveness of tumor debulking, steroidogenesis inhibitors, tyrosine kinase inhibitors (TKIs), bilateral adrenalectomy (BLA), and a new selective RET inhibitor in treating MEN 2-related MTC and ECS. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.